Pharmaceutical Composition Comprising Botulinum Toxin for Treating Knee Joint Pain by Saphenous Nerve Entrapment

a technology of saphenous nerve and pharmaceutical composition, which is applied in the direction of skeletal disorder, peptide/protein ingredient, bacteria antigen ingredients, etc., can solve the problem of virtually impossible to diagnose the entrapment by electroneuromyography when, pain in the knee, and so as to block the response of the hypersensitive receptor, block the secretion of acetylcholine, and paralyze the muscle

Inactive Publication Date: 2008-08-21
IPSEN INT
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028]Other advantage of the present invention is that the composition of the present invention does not disturb the normal secretion of acetylcholine without any paralysis of muscles or other soft tissue. In contrast, if the botulinum toxin is used in the conventional pain treatment method, there are several side effects to be considered (e.g., luxation of temporomandibular joint in injecting the toxin to the muscle of the joint). For example, the hypersensitive receptor responds as if many acetylcholine acts thereon even when a small amount of acetylcholine is present.
[0029]The conventional botulinum toxin injection is administered deeply in a muscle in order to block secretion of acetylcholine, thereby paralyzing the muscle. In contrast, the present invention does not significantly consider whether or not acetylcholine secretes. It administers the toxin injection in order to block the response of the hypersensitive receptor on secretion of a small amount of acetylcholine, to which the normal receptor does not respond. Therefore, the present invention achieves its desired objective by using a small amount of botulinum toxin and it is not necessary to inject the toxin formulation deeply into the muscle for paralyzing the muscle as in the prior art. Such mechanism and method have not been suggested in any of the publications or documents.
[0030]As described above, US patent publication 2003/0224019 discloses that the botulinum toxin type B can be used for treating pain. Further, US patent publication 2004/028704 describes that the pain derived from carpal tunnel syndrome

Problems solved by technology

It has often been believed that the knee pain is caused by problems of the inside of the joint.
Furthermore, autoradiography reveals that the level of knee injury is not necessarily directly proportional to the level of pain in the knee.
The entrapment of the nerve also causes pain in the knee.
As such, it is virtually impossible to diagnose the entrapment by electroneuromyography when the nerve is in the rest state.
However, a drug which efficiently treats the pain associated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical Composition Comprising Botulinum Toxin for Treating Knee Joint Pain by Saphenous Nerve Entrapment

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0057]Double-blinded placebo-controlled clinical trial was carried out for 89 patients of chronic knee pain. This was to compare the effect of botulinum toxin type A injection with that of a physiological saline solution in Chronic Pain Center of Cha hospital located in Seoul, South Korea.

[0058]The botulinum toxin type A injection used in the test was prepared by dissolving Dysport (trademark), which is commercially available from Ipsen Limited (England), comprising 500 units of botulinum toxin type A with 20% albumin solution (0.625 ) and lactose (2.5 mg) in the physiological saline solution of 18 cc.

[0059]The injected areas were identified by Pinch-roll test where the skin fascia governed by the saphenous nerve is pinched and rolled by the finger. The specified areas having the hypersensitive receptors were found to be approximately 5 to 12 areas per patient knee. The specified areas were further pinched to confirm more sensitive points and the above prepared formulation was injec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

There is provided a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier for treating pain in the knee joint caused by saphenous nerve entrapment. The composition of the present invention is for subcutaneous injection above the medial side of the knee.

Description

TECHNICAL FIELD[0001]The present invention relates to a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier for treating pain in the knee joint by saphenous nerve entrapment. In use, the composition of the present invention is injected subcutaneously above the medial side of the knee.BACKGROUND ART[0002]As is well known, a knee joint consists of an inside and an outside. It has often been believed that the knee pain is caused by problems of the inside of the joint. However, receptors, which function to transport pain, are more present around the joint than the inside of the joint. Furthermore, autoradiography reveals that the level of knee injury is not necessarily directly proportional to the level of pain in the knee. With age, a man typically has injury to the inside of the joint while the outside of the joint undergoes various changes.[0003]The saphenous nerve is a nerve that transfers the pain of the medial side of the knee. The entr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/08A61P19/00
CPCA61K38/4893A61P19/00A61P19/02A61P25/04A61P29/00A61P29/02A61K38/16A61K38/17
Inventor AHN, KANG
Owner IPSEN INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products